Managing Hypertension in Patients with Diabetes

作者: Arthur L.M. , David Siegel

DOI: 10.5772/21935

关键词:

摘要: Cardiovascular disease remains the leading cause of death in industrialized nations. Type 2 diabetes confers cardiovascular risk comparable to a previous myocardial infarction, and is most common chronic kidney disease. Diabetes hypertension account for 2/3 [1]. Over 75% adults with are hypertensive, or being treated hypertensive medications [2] In patients type 1 diabetes, presence signals significant damage whereas usually present at time diagnosis [2]. On other hand, many treatments, specifically diuretics, worsen glucose control; overall implications this as yet unclear Because singular resulting from combination hypertension, effort has been expended improve patient outcome. While several recent excellent reviews address different aspects issue [1-3], we will evaluate management particularly perspective managing metabolic syndrome. We effects agents used blood pressure control, consider specific patient-related issues, discuss shortcomings trials, possible future directions genetic analyses. There over 65 million hypertensives United States [4]. Unfortunately, pharmacological treatment these individuals had less than predicted benefit on coronary heart (CHD) mortality [5-7]. For years, It postulated that some antihypertensives might have untoward negate benefits blood-pressure lowering [5, 8]. This may be true syndrome, constellation anthropometric abnormalities includes central obesity, elevated levels fasting triglycerides, low concentrations high-density lipoprotein cholesterol (HDL-C), insulin resistance which associated increased morbidity [9-11]. Of five diagnostic criteria obesity frequently [12, 13]. Why increasingly important US? The prevalence doubled US past 20 years [14]; number extremely obese BMI >35

参考文章(163)
Bogusław Okopień, Robert Krysiak, Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacological Reports. ,vol. 60, pp. 514- 523 ,(2008)
UK Prospective Diabetes Study Group, None, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ. ,vol. 317, pp. 703- 713 ,(1998)
G Dietze, K Rett, M Wicklmayr, H Mehnert, Effects of beta-blocking agents on insulin secretion and glucose disposal. Hormone and metabolic research. Supplement series. ,vol. 22, pp. 29- 33 ,(1990)
Effects of intensive glucose lowering in type 2 diabetes The New England Journal of Medicine. ,vol. 358, pp. 2545- 2559 ,(2008) , 10.1056/NEJMOA0802743
Thomas Pollare, Hans Lithell, L Lind, C Berne, Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. Journal of Human Hypertension. ,vol. 9, pp. 137- 141 ,(1995)
V. Mitrovic, H. H. Klein, N. Krekel, J. Kreuzer, S. Fichtlscherer, A. Schirmer, W. D. Paar, C. W. Hamm, Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis Zeitschrift Fur Kardiologie. ,vol. 94, pp. 336- 342 ,(2005) , 10.1007/S00392-005-0222-5